Trial · NCT05335031
Registered outcomes30
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 30
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of participants persistence with therapy | Up to 36 months | |
| Secondary | Distribution of participant demographics characteristics: Age | At baseline | |
| Secondary | Distribution of participant demographics characteristics: Sex | At baseline | |
| Secondary | Distribution of participant demographics characteristics: Height | At baseline | |
| Secondary | Distribution of participant demographics characteristics: Body weight | At baseline | |
| Secondary | Distribution of clinical characteristics: Smoking status | At baseline | |
| Secondary | Distribution of clinical characteristics: Multiple Sclerosis (MS) diagnosis | At baseline | |
| Secondary | Distribution of clinical characteristics: MS anamnesis/history | At baseline | |
| Secondary | Distribution of clinical characteristics: Prior diseases | At baseline | |
| Secondary | Distribution of clinical characteristics: Concomitant diseases | At baseline | |
| Secondary | Distribution of clinical characteristics: Concomitant medication | At baseline | |
| Secondary | Distribution of clinical characteristics: Prior MS medication | At baseline | |
| Secondary | Distribution of clinical characteristics: Physical examination | At baseline | |
| Secondary | Distribution of clinical characteristics: Reasons for switch to ozanimod | At baseline | |
| Secondary | Distribution of clinical characteristics: Treatment start with ozanimod | At baseline | |
| Secondary | Distribution of clinical characteristics: Discontinuation, defined as physician's documentation of a discontinuation of ozanimod treatment | Up to 36 months | |
| Secondary | Distribution of clinical characteristics: Reason for discontinuation | Up to 36 months | |
| Secondary | Distribution of clinical characteristics: Subsequent MS treatment | Up to 44 months | |
| Secondary | Distribution of clinical characteristics: Persistence with therapy | Up to 36 months | |
| Secondary | Distribution of clinical characteristics: Adherence to therapy | Up to 36 months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05335031/registered